Diamyd Medical AB

Diamyd Medical AB
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes. The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Contacts

Ulf Hannelius

CEO

Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
https://www.diamyd.com
press@diamyd.com

Links

Diamyd Medcial

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Quarterly Report 3 25/26

Wed, Jun 24, 2026 08:15 CET

September 2025 – May 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026Diamyd MedicalDiamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The Company has established a facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. Further information is available on https://www.diamyd.com September 1, 2025 – May 31, 2026 · Net sales: MSEK 0.

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Contacts

Links

Quarterly Report 3 25/26

Subscribe